Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer
Conditions
Stage IIIb and IV Non Small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Intervention
Name: laboratory biomarker analysis Type: Other
Name: Next Generation Sequencing Type: Other
Name: DNA Analysis Type: Genetic
Overall Status
Recruiting
Summary
The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Signed written informed consent

- Male or female aged >= 18 years

- Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed

Exclusion Criteria:

- Tissue and plasma samples can not be provided for mutation analysis

- Unwilling or unable to provide informed consent

- Any serious medical condition that would interfere with the subject's safety
Location
CHU
Rennes, France
Status: Recruiting
Contact: Jean Mosser, PUPH - jean.mosser@chu-rennes.fr
Start Date
June 2014
Sponsors
Rennes University Hospital
Source
Rennes University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page